Ley de Reducción de la Inflación y Medicare

La Ley de Reducción de la Inflación les brinda un importante alivio financiero a millones de personas con Medicare, ya que amplía los beneficios, reduce los costos de los medicamentos y fortalece a Medicare para el futuro.

New Updates in the Medicare Drug Price Negotiation Program

The second round of the Medicare Drug Price Negotiation Program, established under the Inflation Reduction Act, has kicked off with the selection of 15 more drugs covered under Medicare Part D. The drugs selected are:

Between November 2023 and October 2024, about 5.3 million people with Medicare Part D coverage used these drugs to treat a variety of conditions, such as cancer, type 2 diabetes, and asthma. The 15 drugs accounted for $41 billion in total Medicare Part D spending during that time period.

The negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027.

Medicare previously successfully negotiated new, lower prices for the first 10 drugs selected, with those lower prices becoming effective in 2026.

Nuevo en 2025: límite de $2,000 en gastos de bolsillo

Este año, las personas con cobertura de medicamentos recetados de la Parte D de Medicare se beneficiarán de un nuevo límite de gastos de bolsillo de $2,000 en los costos de los medicamentos recetados. El nuevo límite de gastos de bolsillo es solo una de las formas en que la Ley de Reducción de la Inflación está trabajando para reducir los costos de los medicamentos y hacer que la atención médica sea más accesible para todos.

About 11.3 million Part D enrollees are projected to meet the $2,000 out-of-pocket cap in 2025. For these 11.3 million enrollees, total out-of-pocket savings are projected to be about $7.2 billion annually, for an average of about $600 annually per enrollee. Mire cuántas personas con cobertura de la Parte D ahorraron en la primera parte de 2024 gracias al límite otorgado.